Invus invests $550M in Lexicon

New York-based investment firm Invus is purchasing up to $550 million in Lexicon Pharmaceuticals common stock to help finance Lexicon's 10 to 10 program. The 10 to 10 program is an ongoing company initiative with the goal of advancing 10 drug candidates into human clinical trials by 2010. Lexicon expects the new drugs to result from its genetics-based drug discovery platform and to include both small molecules and antibodies.

- see this release on the investment

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.